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Australia’s strong historical foundation in stem cell science was boosted in 2002 by the formation of a virtual
government-supported institute now called the Australian Stem Cell Centre. However, the inevitable ‘‘brain
drain’’ and government and community expectations of quick commercial gains and rapid cures necessitate
careful reconsideration of the identity and future of stem cell science in Australia.Stem Cell Research in Australia: A Strong Beginning
Stem cell research in Australia has been historically very strong,
as exemplified by the career-long efforts of Don Metcalf and col-
leagues at the Walter and Eliza Hall Institute (WEHI) in Mel-
bourne. Beginning with a simple colony-forming assay,Metcalf’s
exploration of colony stimulating factors (CSFs) allowed him and
his colleagues to dissect relationships between hematopoietic
stem cells and their differentiated progeny and the growth factor
and signaling pathways that regulate the immune system in
health and disease (Metcalf, 2000). Some of these cytokines,
since identified and their genes cloned, have been of enormous
value in medicine. Metcalf’s contributions have been highly rec-
ognized (including an Albert Lasker Clinical Medical Research
Award in 1993) and can be seen as the pinnacle of Australian
stem cell science of the last 4 decades. One of the most signifi-
cant clinical findings of this era was the demonstration that
hematopoietic stem cells can be mobilized into the peripheral
blood, first shown in the context of chemotherapy by Bik To
and Chris Juttner at the Institute of Medical and Veterinary Sci-
ence (IMVS) and Royal Adelaide Hospital in Adelaide (To et al.,
1984) and then for cytokines by a team under Metcalf at WEHI/
Royal Melbourne Hospital (Du¨hrsen et al., 1988). There have
been many other noteworthy Australian contributions, including
an outstanding history in reproductive biology research and clin-
ical translation culminating in the first live births using fertility
drugs (Trounson et al., 1981) and in vitro fertilization (IVF) and fro-
zen IVF embryos (Trounson and Mohr, 1983) in 1980 and 1982,
respectively. Other milestones include Perry Bartlett’s definition
of renewable brain stem cells (WEHI) (Bartlett, 1982), the identi-
fication by Nick Gough and colleagues of leukemia inhibitory
factor (LIF) (Williams et al., 1988), which maintains mouse em-
bryonic stem (ES) cells in a pluripotent state (WEHI), and the
debunking of the quantal mitosis hypothesis and skeletal muscle
regeneration studies by Miranda Grounds (University of Western
Australia) (Grounds and McGeachie, 1987).
Human Embryonic Stem Cell Research in Australia
Human embryonic stem (hES) cell research in Australia began at
Monash University in Melbourne in 1994 and was championed
by Martin Pera and myself (A.T.), Ben Reubinoff, and Ariff
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work, made possible by availability of excess human embryos
from the National University Singapore IVF Clinic under approval
from the National Singapore Medical Ethics Committee, led to
the derivation of some of the very first hES cell lines (Reubinoff
et al., 2000). The studies were initially supported by in-house
grant money and subsequently financed from an Australian/Sin-
gaporean investment consortium when the group founded Em-
bryonic StemCell International (ESI Pty Ltd). However, the group
was second to patent and publish on their isolation, thereby
narrowly avoiding the controversial legal wrangling on the value
of derivation patents. ESI, which has always been a Singapore-
registered company, initially focused on making and distributing
hES cells, with the intention of supporting (and capturing IP
from) the laboratories of founding members, although it later
established a clinical focus on diabetes and heart failure. The
company has recently downsized in the face of its difficulties in
maintaining private equity funding for an ES cell-based cell ther-
apy program, given the regulatory issues and long lead time to
product.
The most significant asset that arose in Australia from this
early pioneering work was the leverage it gave to the bid for
a new Australian government funding initiative that led to the for-
mation of the Australian StemCell Centre (see below). In fact, the
direct impact of the creation of hES cell lines in Australia (Reubin-
off et al., 2000) was arguably muted because of the delay in dis-
tribution of hES lines to the wider community by companies and
the ethical debate (Finkel, 2005) that immediately sprung up
about their use, resulting in contested approvals by the American
NIH, national and international institutional boards, and ethics
committees.
More recently, in a rare conscience vote, the Australian gov-
ernment narrowly supported legislation allowing somatic cell nu-
clear transfer (SCNT) technology to proceed under strict regula-
tion. Themove followed from a review of the former legislation by
a retired federal court judge, the late John Lockhart (Sinclair and
Schofield, 2007), and the lead taken by the British in this area.
This change gives Australia a competitive position to proceed
with research aimed at the production of patient and disease-
specific hES cells using the cytoplasm of oocytes or eggs excess
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on SCNT is nowmore consistent than that in the US, where there
are different regulations depending on whether the research is
government or privately funded. However, it is still illegal in
Australia to produce embryos by the union of eggs and sperm
specifically for research, whereas the UK, Belgium, China,
Singapore, South Korea, and Sweden allow this practice. The
Government Ministry of Science and Medical Research in the
State of New South Wales has recently announced a new fund-
ing initiative, albeit relatively modest in terms of dollars, to sup-
port the progression of SCNT technology. Recent findings by
Shinya Yamanaka at Kyoto University suggest that pluripotency
can not only be understood at a biochemical and genetic level
but also manipulated without the use of human embryos. Thus,
community tensions over the use of excess human embryos in
research evident during this period (see below) may soon ease.
The Australian Stem Cell Centre
When a group at Monash University, including myself (A.T.) and
David de Kretser (a reproductive andrologist and now governor
of the State of Victoria), drafted an application, which was then
presented by A.T., Dianna DeVore (US patent attorney and
PhD), and Robert Moses (biotechnology businessman) to the
Federal Government Selection Committee and won the bid for
the first Australian Biotechnology Centre of Excellence, the
Australian Stem Cell Centre (ASCC) came into being. Funding
came from the Australian federal government to the tune of
A$110 million over 10 years and was supplemented by other
funds from the federal and Victorian state governments. This
venture provided valuable support for a nation-wide endeavor
to build strong platforms in adult and embryonic stem cell re-
search, with a drive toward clinical therapies. The key scientists
present at the onset included Paul Simmons (MSCs), Peter Rath-
jen (mouse ES cells), Martin Pera (human ES cells), Bernie Tuch
(diabetes), Richard Harvey (adult cardiac stem cells), Mal Horne
(neural stem cells), Andrew Elefanty and Ed Stanley (ES cell
blood and pancreatic differentiation), Richard Boyd (thymic
stem cells and regeneration), and A.T. (embryonic, placental,
and pulmonary stem cells and tissue repair). This list was subse-
quently narrowed to a smaller group by stringent peer review of
the scientific teams and an assessment of commercial potential.
Although in essence a virtual institute, the ASCC has an admin-
istrative, legal, and patent node that includes some laboratories
atMonash University inMelbourne and is developing a new node
at the University of Queensland. The ASCC is built on a govern-
ment model derivative of its history of funding Cooperative Re-
search Centers (CRCs), involving partnerships between science
and industry. The ASCC missions are to evolve an organization
capable of identifying, undertaking, and supporting stem cell re-
search and related technologies at an international level in Aus-
tralia, attracting and retaining leading stem cell scientists in Aus-
tralia, commercializing the outcomes of stem cell research for
Australia, and engaging in advocacy and education, including
training of PhDs. The ASCC is, in fact, a company (limited by
guarantee) with ownership of intellectual property (IP) generated
under their funding structure. The parent institutes of funded re-
searchers and other major institutes in Australia are ‘‘stake-
holders’’ in that they provide in kind support to the Centre and
royalty-free license to background IP, albeit exclusive withrespect to its commercial use. Stakeholders are built into the
commercial structure of the ASCC in that commercial benefits
and equity in any spin-off companies will be shared according
to the proportion of contributions made in kind by an individual
stakeholder. Each of the stakeholder institutes has membership
on a committee that provides input into the running of the ASCC.
Without doubt, the ASCC has injected strength into stem cell
research in Australia. It is likely that lasting synergies have
been created between stem cell and developmental biologists,
clinicians, and other scientists over a range of disciplines. One
of the immediate consequences of the formation of ASCC, how-
ever, was the parochial perception by grant review committees
that if work was not funded by ASCC it was not of the highest
quality. At the same time, those who were granted funds by
the ASCC had fewer opportunities to leverage funding from other
agencies, due to the misperception that the work was ade-
quately financed without additional support. General stem cell
research now relies more on the project grant funding mecha-
nisms of our major biomedical and biological research funding
agencies, the National Health and Medical Research Council
(NHMRC) and Australian Research Council (ARC), and on foun-
dations with particular patient interests such as the Junior Diabe-
tes Research Foundation, Multiple Sclerosis Research Societies,
National Heart Foundation, and others. Research applications to
these agencies must compete with all other areas of biomedical
research. The growing body of scientists working on the role of
stem cells in cancer may lead to additional pressures on funding
demographics.
The ASCC is now in the second half of its funding cycle. With
this has come a greater emphasis on commerciality in order to
meet its original terms of reference: short-term commercial
products and work with promise for clinical therapies in the
longer term. An inevitable consequence of the commercial focus
is that some of the more basic studies into stem cell biology, ini-
tially a strong component of the ASCC, now receive less support
from this agency. The much hoped-for commercial success of
stem cell research in Australia is not without precedent, as exem-
plified by the royalty stream to WEHI and the Ludwig Institute of
Medical Research (Melbourne) as a result of the identification
and clinical and basic science use of cytokines GM-CSF
($1.5 million/an) and LIF ($0.5 million/an). However, in relative
terms, this is not a large revenue stream, considering the de-
cades of basic research conducted by some of Australia’s best
immunobiologists. The likelihood of a quick return on national
investments in stem cell research should be considered in this
light. On the other hand, income from other discoveries in immu-
nology (e.g., G-CSF) was lost to ill-timed patent protection, and
this lesson should also be kept in mind.
The National Centre for Adult Stem Cell Research
Oneunusual outcomeof the inevitable politicization of the debate
on the ethics of human embryonic stem cell research was the
awarding, without a competitive process, of a A$22 million grant
by the Australian Minister of Health (strongly opposed to embry-
onic stem cell research) in 2006 for the establishment of the Na-
tional Centre for Adult Stem Cell Research. Although the bid was
based ononegroup’s exploration of a specific class of adult stem
cells, the naming of the Centre reflects the strength of partisan
ethical and religious convictions in both government and the
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by neurobiologist Alan Mackay-Sim and is located within the
Eskitis Institute for Cell and Molecular Therapies at Griffith Uni-
versity in the State of Queensland. Their mission is to strengthen
adult stemcell research nationally and internationally, with a view
toward cell therapies for neurological conditions such as Parkin-
son’s disease and spinal cord injury. The Centre’s research fo-
cuses on olfactory neural epithelial stem cells, a readily harvest-
able, multipotent adult stem cell population that normally resides
on the basement membrane of the olfactory epithelium, where
they generate the organ’s neuronal and nonneural components.
Olfactory neuron ensheathing cells, which provide vital stem cell
support, are also under study, and a phase I safety trial using this
population in paraplegics is underway. The funding over 4 years
is considered short term and does not necessarily come with the
commercial expectations of the ASCC model. Its success will
therefore be measured more in developed synergies and infra-
structure. In this regard, it is important to note that AstraZeneca,
leveraging state and federal government funds, has invested
millions of dollars into natural product screening laboratories in
the Eskitis Institute,which nowhasabankof over 300,000natural
product samples from the Queensland rain forests and reefs as
well as a growing collection of pure compounds generated by
chemists in Queensland’s Universities. This resource may pro-
vide unique opportunities for collaborations on drug screening
using stem cells or their products as the field matures.
It is interesting to note that there are a number of other insti-
tutes in Australia that have programs dedicated to adult stem
cell research. Hospital-affiliated centers, including the Victor
ChangCardiac Research Institute andGarvin Institute ofMedical
Research (Sydney), St. Vincent’s Research Institute (Melbourne),
and the Mater Medical Research Institute (Brisbane), fall under
the governance and congregational leadership of the Catholic
Church, which on ethical grounds does not support the destruc-
tion of human embryos for research.
There are other strong adult stem cell groups in Australia. For
example, the new Queensland Brain Institute of the University of
Queensland in Brisbane, headed by Perry Bartlett, has a strong
commitment to adult neural stem cells, while Melissa Little, the
new Chief Scientific Officer of ASCC based at the University of
Queensland, oversees a program on adult kidney stem cells.
Stem Cell Brain Drain and Company Drain
Although the quality of postgraduate training in our major Austra-
lian universities is well recognized internationally, we suffer from
a brain drain toward strong scientific centers in the US and
Europe. This effect is enhanced by an attitude among emerging
scientists, encouraged by their mentors, that some years spent
in postdoctoral positions overseas is largely essential for career
progression at home. Many expatriates return, but it is inevitable
that wewill lose some of our best permanently, or at least for their
most creative and influential years. Two of our most accom-
plished senior stem cell scientists and founding members of
the ASCC, Paul Simmons and Martin Pera, have recently left
Australia to take up directorships of stem cell institutes in the
US. In addition, one of us (A.T.) has recently assumed the
presidency of the California Institute of Regenerative Medicine,
which over the coming years will distribute some $3 billion of
Californian public money to pluripotential stem cell research.
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postdoctoral and elite levels by offering attractive fellowship
schemes. However, stem cell research has not yet reached its
crescendo, and the massive amount of support available over-
seas may simply overwhelm our relatively modest local fellow-
ship and stem cell funding initiatives. This pattern will continue
to be a major issue as we attempt to keep pace with global
developments in stem cell science.
There has also been a noticeable exodus of stem cell compa-
nies, causing an additional blow to our strategic advantage. As
noted, ESI was registered in Singapore from the beginning.
BresaGen and Stem Cell Sciences, both involved in ES cell re-
search, have moved most of their activities offshore. Stem Cell
Sciences, founded by Australian Peter Mountford, is listed dually
in the UK and Australia and retains offices and laboratories in
Melbourne working on embryonic stem cell derivatives for drug
discovery. However, their major scientific and fundraising activ-
ities are within the UK. Perhaps the main reason for this divide is
that the market size in Australia, with a population of 20.5 million,
is ultimately small, and the best value for shareholders is for com-
panies to position themselves to register products in the major
population centers of the Western World. However, Australia
currently provides a regulatory environment conducive to per-
forming early phase safety and proof-of-principle clinical trials.
This is due to the fact that such trials can be initiated directly
via a principal investigator to a registered ethics committee for
approval, without the necessity of directly engaging Australia’s
government regulatory agency for medical drugs and devices
(FDA equivalent), the Therapeutic Goods Administration (TGA).
This approach is not possible in the US and Europe, which also
have greater expertise and expectations for conducting the
more demanding phase II and III trials. The TGA is guided largely
by the FDA with respect to the regulatory benchmarks required
for these latter trials to proceed. However, the environment for
early trials, combined with a less complex pre- and early listing
fundraising environment, may see the number of companies in
Australia grow and thrive as our science matures. The stem cell
therapeutics company Mesoblast is noteworthy this regard.
Founded in Melbourne by expatriate Australian Sylviu Itescu, it
focuses on developing bone marrow mesenchymal progenitor
cell (MPC) therapies for bone, cartilage, and cardiovascular re-
pair. Listed in 2004, Mesoblast has acquired a stake in Angio-
blast, its US parent company that owns the composition of mat-
ter patents for MPC isolation and growth developed by Paul
Simmons, Andrew Zannettino, and Stan Gronthos at the Hanson
Institute and Institute of Medical and Veterinary Science in Ade-
laide. Two small phase I trials have been conducted for chronic
angina and nonunion fractures in Australia with phase II trials un-
derway in the US. Cell therapies using endogenous cells such as
MPCsmay reach the market long before those involving hES cell
derivatives, due to regulatory and safety issues. However, the
competition is fierce, with a major player in the MPC world, Osa-
ris Therapeutics, holding over 150 patents, including one for the
use ofMPCs in unrelatedMHC-mismatched donors, the key pat-
ent covering the universal stem cell donor concept.
Current State of Stem Cell Research in Australia
Stem cell research continues to grow in Australia. The breadth
and number of the Australian research reports (178) presented
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in June 2007, in Cairns, Queensland, presided over by (now ex-
patriate) Australian Paul Simmons as society president, is indic-
ative of the healthy state of the research and of the variety of
funds supporting the work. A recent highlight was the demon-
stration by Jane Visvader and Geoff Lindeman at WEHI that
a complete mammary gland could be generated from a single
stem cell (Shackleton et al., 2006). This is the first demonstration
of a single cell being able to reconstitute a solid organ and pro-
vides a strong platform for understanding the lineage hierarchy
in breast development and the cellular origins of breast cancer.
There are a number of groups active in directed differentiation
of human and mouse ES cells, including Gail Risbridger and col-
leagues at Monash Institute of Medical Research and Monash
Immunology and Stem Cell Laboratories (MISCL) who recently
exploited rodent urogenital mesenchyme as an inductive source
to produce prostate tissue from hES cells (Taylor et al., 2006). A
team led by Andrew Elefanty and Ed Stanley at MISCL is explor-
ing blood and pancreatic differentiation from human ES cells.
Richard Boyd, A.T., Claude Bernard, and Ban Hoc Toh at MISCL
are using an innovative stem cell approach to study the induction
of tolerance for delivery of ES cell progeny and the reversal of
autoimmune diseases.
Another important development in stem cell research in Aus-
tralia is on the horizon. The Department of Health and Aging,
the Victorian state government, and Monash University have
jointly invested A$153 million to establish the Australian Regen-
erative Medicine Institute, which is committed to unraveling ba-
sic cellular and molecular mechanisms underlying regenerative
process in vital organs damaged by disease, injury, or genetic
conditions. With laboratories to open in 2008, the new institute
is directed by Nadia Rosenthal, a US-born muscle regeneration
biologist, who is currently Head of the European Molecular Biol-
ogy Laboratory (EMBL) outstation in Monterotondo near Rome.
More recently, the Australian Government Department of Ed-
ucation Science and Training and the government of China
have awarded the Australia-China Centre of Excellence in
Stem Cell Sciences to the Stem Cell Research Centre at the Uni-
versity of Peking and MISCL at Monash University. This is a sig-
nificant regional linkage supported by both governments that
builds on the reputations and contributions of these two research
teams to establish a very significant body of stem cell scientists.
The teams are to be headed by Richard Boyd and Graham Jen-
kin (MISCL) and Lingsong Li (Peking University).
It is clear that both adult and ES cell research are surging for-
ward and that the initial support provided by the Australian gov-
ernment will need to be supplemented by other public and phil-
anthropic institutions, industry investment capital, as well as the
usual sources from the NHMRC and ARC in the future if this
expansion of activity and international competitiveness is to be
sustained.
Retaining a Strong Australian Stem Cell
Research Environment
Retaining our leading Australian scientists will require more than
the provision of sufficient research funding, traineeships for
young scientists, further major facilities, and state-of-the-art
equipment. In addition, a regulatory environment that enables
researchers to compete internationally and support for linkagesto international collaborations are both necessary for Australia to
remain a significant part of the medical revolution in stem cell
therapies. However, the very competitive Australian research
environment will almost certainly limit funding of this research.
Indeed, it is increasingly apparent that innovative approaches
for support of stem cell research, such as that designed in Cali-
fornia utilizing bond assets, international linkages, and the co-
funding of research by public and private institutions will be nec-
essary to deliver the clinical benefits of stem cell therapies to
patients in Australia. There are well-defined pathways for these
avenues to be developed, and Australia should engage in re-
gional partnerships and international agreements to remain
competitive. It would be wise to encourage the involvement of
those who have recently left for overseas to help facilitate these
arrangements.
The evolution of strong, independent stem cell basic research
and translational centers in Australia is important. One hopes
this will happen with a variety of strategies and niche interests
and that free exchange of scientific information, and community
education and involvement in the variety of approaches neces-
sary, will accompany this expansion. It is also hoped that more
Australian universities, working with local governments, will
commit to building regenerative medicine institutes of interna-
tional caliber.
Lessons for Other Stem Cell Initiatives?
The confidence demonstrated by the Australian government in
forming the ASCC and backing scientists in this new and innova-
tive area of research is laudable, and the very positive interna-
tional response to the promise of stem cell therapies highlights
the wisdom of this decision.
However, much rests on the shoulders of the ASCC and other
emerging stem cell organizations. Under the ASCC, Australian
stem cell researchers were provided a unique impetus to galva-
nize and collaboratively perform in a range of commercial and
basic science endeavors at levels rarely achieved before. There
have been the inevitable teething problems and lessons learned
in building and running a high-profile virtual institute with this
breadth of mission. Specific challenges included establishing
a common sense of identity, stable management, transparent
peer review processes, good communication, and synergies
between geographically isolated groups. The loss of some of
our best stem cell researchers to greener pastures overseas
highlights an ongoing danger: without the right sort of support
for key scientific leaders and to build a strong culture of stem
cell research from bench to clinic, a futile cycle will develop in
which investment in current personnel and the training of future
leaders will be lost to other interests.
Within the ASCC, funds are now being focused on a research
process in which discoveries can be rapidly converted to com-
mercial products. With this as Australia’s premier stem cell initia-
tive, and arguably the only one with direct links to government,
there are risks that high-value basic science will suffer and that
appointments and allocations will no longer reflect acknowl-
edged scientific leadership. Whether this commercial model
proves to be a prudent investment for Australian science and
technology remains to be seen. In considering current versus fu-
ture commercial opportunities, some key issues are the relative
immaturity of most areas of the stem cell field and the vigor
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ical trials, despite limited (and possibly misguided) information
as to biological mechanisms. Also, we are in the midst of a revo-
lution in our understanding of the basic aspects of cell potency
and tissue homeostasis, repair, and regeneration. Because it is
highly likely that creative basic science endeavors in these areas
will form the germ of future commercialization opportunities in
this fast-moving field, it is of some concern that key strengths
of Australian stem cell biology and technology are not currently
being targeted for support. There is much ahead of us, and Aus-
tralia needs to build a very broad foundation in order to reap the
rewards of the future.
The relative emphasis placed on basic and commercial re-
search requires constant review and informed debate. It is an
equation that can shift depending on community expectations
and the lobbying of politicians, patients, and scientists alike.
On this point, most public education has thus far focused on
the ethics and promise of stem cell research. However, it will
also be necessary to instill into the public mind a realistic under-
standing of how science progresses and to establish a credible
timescale for health outcomes arising from the stem cell biomed-
ical revolution. This is an achievable challenge, given the general
heightened public awareness of stem cells, a positive and recep-
tive public attitude toward investment in scientific and medical
research, and what we perceive to be a developing sophistica-
tion in reportage of science by the media. Stem cell institutes
and scientists should continue to be proactive in community
and media education.
In summary, greater investment is needed by the Australian
government and by national and international commercial sec-
tors in research and development across the broad spectrum
of stemcell initiatives inAustralia in order tomaintain our research
competitiveness. This message is equally applicable to other
nations with emerging stem cell initiatives. This is an important
time in the history of biomedical research. The issue for reflection122 Cell Stem Cell 2, February 2008 ª2008 Elsevier Inc.is not whether we can afford to fund stem cell research, but
whether we can afford not to.
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